Haematology
Browse by
Research outputs form the Clinical Haematology service at the RD&E.
Recent Submissions
-
Correlation of Quality of Life between Treatment Outcomes in the Majic Study Which Compared Ruxolitinib to Best Available Therapy in Polycythemia Vera
(Blood, 2021-11-05)MAJIC is a phase II trial of Ruxolitinib (RUX) vs Best Available Therapy (BAT) in polycythemia vera (PV) patients with resistance/intolerance to Hydroxycarbamide (HC). This analysis involved a primary comparison between ... -
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia
(Wiley, 2021-12-26)Induction therapy for acute myeloid leukaemia (AML) has changed with the approval of a number of new agents. Clinical guidelines can struggle to keep pace with an evolving treatment and evidence landscape and therefore ... -
A Systematic Literature Review and Meta-Analysis of the Incidence of Serious or Severe Hypersensitivity Reactions after Administration of Ferric Derisomaltose and Ferric Carboxymaltose
(Blood, 2021-11-23)Background and Aims Intravenous (IV) iron is the preferred treatment for patients with iron deficiency (ID) and iron deficiency anemia (IDA) in a variety of clinical situations. Although uncommon, administration of modern ... -
An open-source, expert-designed decision tree application to support accurate diagnosis of myeloid malignancies
(Wiley, 2021-03-26)Accurate, reproducible diagnoses can be difficult to make in haemato-oncology due to multi-parameter clinical data, complex diagnostic criteria and time-pressured environments. We have designed a decision tree application ... -
Guidelines on the use of irradiated blood components
(Wiley, 2020-12) -
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival
(Wiley, 2020-08)Data on older patients with primary central nervous system lymphoma (PCNSL) are scarce. Comorbidities and performance status frequently compromise outcomes in this group. Medical records for consecutive patients ≥65 years ... -
A HaemSTAR-led, UK-wide ‘flash-mob’ audit of intravenous immunoglobulin use in immune thrombocytopenia
(Clinical Medicine, 2019-06) -
Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease
(JAMA, 2019-02)Use of thiopurines may be limited by myelosuppression. TPMT pharmacogenetic testing identifies only 25% of at-risk patients of European ancestry. Among patients of East Asian ancestry, NUDT15 variants are associated with ... -
Novel use of tranexamic acid to reduce the need for Nasal Packing in Epistaxis (NoPac) randomised controlled trial: research protocol
(BMJ, 2019-02-15)Patients presenting to emergency departments (EDs) with epistaxis uncontrolled by subsequent simple first aid measures or application of topical vasoconstrictors will typically undergo anterior nasal packing. Packing is ... -
Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
(Springer, 2018-02-26)As part of its single technology appraisal process, the National Institute for Health and Care Excellence (NICE) invited the company that manufactures ponatinib (Inclusig®; Incyte Corporation) to submit evidence for the ... -
Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial.
(American Society of Hematology, 2017-08-09)Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related symptoms, as well as risks of thrombosis, hemorrhage, transformation to myelofibrosis and leukemia. Patients resistant/intolerant ... -
Guidelines for the use of platelet transfusions.
(Wiley, 2016-12-23) -
Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
(Springer, 2016-10-17)The National Institute for Health and Care Excellence (NICE) invited the manufacturer of azacitidine (Celgene) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of acute myeloid ... -
EDTA improves stability of whole blood C-peptide and insulin to over 24 hours at room temperature.
(PLoS One, 2012)C-peptide and insulin measurements in blood provide useful information regarding endogenous insulin secretion. Conflicting evidence on sample stability and handling procedures continue to limit the widespread clinical use ... -
Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.
(Wiley, 2016-05-16)This article is currently freely available from the publisher's site (May 2016). Click on the 'Additional Link' above to access the full-text from the publisher's site. -
ACTN1-related thrombocytopenia: identification of novel families for phenotypic characterization
(Blood, 2015-01-29)Inherited thrombocytopenias (ITs) are a heterogeneous group of syndromic and nonsyndromic diseases caused by mutations affecting different genes. Alterations of ACTN1, the gene encoding for alpha-actinin 1, have recently ... -
Two samples for blood transfusion: single centre experience
(Wiley, 2014-08-01)OBJECTIVES: The aim of this study was to evaluate the introduction of two-sample policy for transfusion at our hospital and reduction of the risk of ABO incompatible transfusion. BACKGROUND: ABO incompatible transfusion ...
RSS 1.0